GPC Biotech reaches target enrollment in phase 3 trial of satraplatin for prostate cancer

New York, Dec. 5 - GPC Biotech AG said it achieved the target enrollment in its phase 3 trial of satraplatin for hormone-refractory prostate cancer.

A total of 912 patients have joined the trial at 200 sites in 15 countries. Some additional patients are still in screening.

The so-called Sparc (Satraplatin and Prednisone Against Refractory Cancer) trial is a double blind, randomized study to assess the safety and efficacy of satraplatin in combination with prednisone as a second-line chemotherapy in patients with hormone-refractory prostate cancer.

GPC Biotech is a Martinsried, Munich, Germany-based biopharmaceutical company working on anti-cancer drugs.

Satraplatin is a platinum-based drug administered orally - unlike current platinum compounds, which must be injected - and has already been the subject of phase 2 trials for hormone-refractory prostate cancer, ovarian cancer and small cell lung cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.